A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Required: HER2 (ERBB2) low expression (IHC 1+ or IHC 2+/ISH-negative) (IHC 1+ or IHC 2+/ISH-negative)

HER2-low status determined by most recent local assessment (IHC 1+ or IHC 2+/ISH-negative)

Required: HER2 (ERBB2) overexpression (IHC 3+ or IHC 2+/ISH+) (IHC 3+ or IHC 2+/ISH+)

HER2+ status determined by most recent local assessment (IHC 3+ or IHC 2+/ISH+)

Allowed: BRCA1 mutation

Participants with known BRCA mutation must have received a PARP-inhibitor where available and not medically contraindicated

Allowed: BRCA2 mutation

Participants with known BRCA mutation must have received a PARP-inhibitor where available and not medically contraindicated

Allowed: ESR1 expression (hormone receptor positive)

Participants with HR+ tumors must have intolerance to endocrine therapy or endocrine therapy refractory disease

Allowed: PR (PGR) expression (hormone receptor positive)

Participants with HR+ tumors must have intolerance to endocrine therapy or endocrine therapy refractory disease

Allowed: PD-L1 (CD274) overexpression (CPS 10 or greater)

Participants with HR negative, HER2-low and PD-L1-positive (CPS 10 or greater) tumors must have received pembrolizumab with chemotherapy if available as local standard of care therapy

Must have received: systemic cytotoxic chemotherapy — locally advanced/metastatic

Must have experienced disease progression on or after standard of care therapies or be intolerant of standard of care therapies.

Must have received: PARP inhibitor — locally advanced/metastatic

Participants with known BRCA mutation must have received a PARP-inhibitor where available and not medically contraindicated

Must have received: topoisomerase I inhibitor (T-DXd, sacituzumab govitecan) — locally advanced/metastatic

Have progression on or after, or intolerant to, T-DXd, sacituzumab govitecan, or other topoisomerase I inhibitor therapies, if available as local standard of care therapy

Must have received: CDK4/6 inhibitor — adjuvant or metastatic

had received a CDK4/6 inhibitor in the adjuvant or metastatic setting

Must have received: endocrine therapy — locally advanced/metastatic

Progressed on 2 lines of endocrine therapy for LA/mBC AND had received a CDK4/6 inhibitor in the adjuvant or metastatic setting OR Progressed on 1 line of endocrine therapy for LA/mBC AND had a relapse while on adjuvant endocrine therapy after definitive surgery for primary tumor AND had received a CDK4/6 inhibitor in the adjuvant or advanced setting

Must have received: anti-PD-1 therapy (pembrolizumab) — locally advanced/metastatic

Participants with HR negative, HER2-low and PD-L1-positive (CPS 10 or greater) tumors must have received pembrolizumab (or other PD-(L)1 inhibitor) with chemotherapy if available as local standard of care therapy and not medically contraindicated.

Must have received: HER2-targeted therapy (trastuzumab, pertuzumab) — advanced

Received prior trastuzumab, pertuzumab and a taxane if available as local standard of care therapy for advanced disease.

Must have received: taxane — advanced

Received prior trastuzumab, pertuzumab and a taxane if available as local standard of care therapy for advanced disease.

Must have received: HER2-targeted therapy (trastuzumab) — locally advanced/metastatic

Received prior trastuzumab plus fluoropyrimidine and platinum containing chemotherapy if no contraindication.

Must have received: fluoropyrimidine — locally advanced/metastatic

Received prior trastuzumab plus fluoropyrimidine and platinum containing chemotherapy if no contraindication.

Must have received: platinum-based chemotherapy — locally advanced/metastatic

Received prior trastuzumab plus fluoropyrimidine and platinum containing chemotherapy if no contraindication.

Must have received: systemic cytotoxic chemotherapy (platinum, fluorouracil, taxane) — locally advanced/metastatic

Prior systemic therapy with platinum, fluorouracil, or taxane for locally advanced unresectable or metastatic disease

Cannot have received: antibody-drug conjugate with MMAE payload

Prior therapy with ADCs with MMAE payload

Cannot have received: HER2-targeted therapy

Must not have received prior treatment with HER2 directed therapy

Cannot have received: tucatinib (tucatinib)

Prior therapy with tucatinib

Cannot have received: systemic anticancer treatment

Exception: within 4 weeks prior to first dose of study treatment

Participants who have received prior systemic anticancer treatment including investigational agents within 4 weeks prior to first dose of study treatment